Literature DB >> 31325553

Dupilumab ocular surface disease occurs predominantly in patients receiving dupilumab for atopic dermatitis: A multi-institution retrospective chart review.

Reid A Waldman1, Madeline E DeWane1, S Brett Sloan2, Brett King3, Jane M Grant-Kels4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31325553     DOI： 10.1016/j.jaad.2019.07.031

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  3 in total

1.  Characterising the chronicity of dupilumab-associated ocular surface disease: an analysis of a retrospective case series.

Authors:  Mélanie Hébert; Susan Ruyu Qi; Eunice You; Mathieu Mercier; Patricia-Ann Laughrea
Journal:  BMJ Open Ophthalmol       Date:  2022-05

2.  Dupilumab facial redness: Positive effect of itraconazole.

Authors:  Fleur S A de Beer; Daphne S Bakker; Inge Haeck; Lieneke Ariens; Jorien van der Schaft; Marijke R van Dijk; Marjolein S de Bruin-Weller
Journal:  JAAD Case Rep       Date:  2019-10-22

3.  Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.

Authors:  Emma Guttman-Yassky; Andrew Blauvelt; Lawrence F Eichenfield; Amy S Paller; April W Armstrong; Janice Drew; Ramanan Gopalan; Eric L Simpson
Journal:  JAMA Dermatol       Date:  2020-04-01       Impact factor: 10.282
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.